Fig. 5From: Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trialsSubgroup analysis of DPP4i effects on cholecystitis and cholelithiasis events. Subgroup analysis were stratified by subclass of medicines, short versus long duration of follow-up (< 26 vs ≥ 26 weeeks vs ≥ 52 weeeks), age (< 60 vs ≥ 60 years old)Back to article page